Get started
DASHENLIN PHARMACEUTICAL GROUPDASHENLIN PHARMACEUTICAL GROUPDASHENLIN PHARMACEUTICAL GROUP

DASHENLIN PHARMACEUTICAL GROUP

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

603233 chart


Full chart

603233 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪17.80 B‬ CNY
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
20.96
Basic EPS (TTM)
0.75 CNY
Net income (FY)
‪1.17 B‬ CNY
Revenue (FY)
‪24.44 B‬ CNY
Shares float
‪341.84 M‬
Beta (1Y)
1.28

Employees


Employees (FY)
‪45.47 K‬
Change (1Y)
‪+5.97 K‬ +15.11%
Revenue / Employee (1Y)
‪537.47 K‬ CNY
Net income / Employee (1Y)
‪25.66 K‬ CNY

About DASHENLIN PHARMACEUTICAL GROUP


Sector
Health Technology
CEO
Guo Qiang Ke
Headquarters
Guangzhou
Website
dslyy.com
Founded
1999
ISIN
CNE100002RG2
FIGI
BBG00GBVZR14
DaShenLin Pharmaceutical Group Co., Ltd. engages in the retail and wholesale of pharmaceutical products. Its products include vitamins, ointment, oral medicine, cold and flu medicine, digestive medicine, beauty herbals, oral care, bath care, dairy products, and contraceptives. The company was founded by Yun Feng Ke, Kang Bao Ke, Jin Long Ke and Chao Zhu Zou on February 12, 1999 and is headquartered in Guangzhou, China.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

603233 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 603233 is 15.26 CNY — it has decreased by −2.49% in the past 24 hours. Watch DASHENLIN PHARMACEUTICAL GROUP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange DASHENLIN PHARMACEUTICAL GROUP stocks are traded under the ticker 603233.
603233 stock has fallen by −7.45% compared to the previous week, the month change is a −0.91% fall, over the last year DASHENLIN PHARMACEUTICAL GROUP has showed a −37.97% decrease.
We've gathered analysts' opinions on DASHENLIN PHARMACEUTICAL GROUP future price: according to them, 603233 price has a max estimate of 26.00 CNY and a min estimate of 12.00 CNY. Watch 603233 chart and read a more detailed DASHENLIN PHARMACEUTICAL GROUP stock forecast: see what analysts think of DASHENLIN PHARMACEUTICAL GROUP and suggest that you do with its stocks.
603233 reached its all-time high on Jan 25, 2021 with the price of 61.63 CNY, and its all-time low was 11.00 CNY and was reached on Jul 31, 2017. View more price dynamics on 603233 chart.
See other stocks reaching their highest and lowest prices.
603233 stock is 3.28% volatile and has beta coefficient of 1.28. Track DASHENLIN PHARMACEUTICAL GROUP stock price on the chart and check out the list of the most volatile stocks — is DASHENLIN PHARMACEUTICAL GROUP there?
Today DASHENLIN PHARMACEUTICAL GROUP has the market capitalization of ‪17.81 B‬, it has decreased by −1.48% over the last week.
Yes, you can track DASHENLIN PHARMACEUTICAL GROUP financials in yearly and quarterly reports right on TradingView.
DASHENLIN PHARMACEUTICAL GROUP is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
603233 earnings for the last quarter are 0.18 CNY per share, whereas the estimation was 0.24 CNY resulting in a −24.96% surprise. The estimated earnings for the next quarter are 0.11 CNY per share. See more details about DASHENLIN PHARMACEUTICAL GROUP earnings.
DASHENLIN PHARMACEUTICAL GROUP revenue for the last quarter amounts to ‪6.39 B‬ CNY, despite the estimated figure of ‪6.36 B‬ CNY. In the next quarter, revenue is expected to reach ‪7.28 B‬ CNY.
603233 net income for the last quarter is ‪200.53 M‬ CNY, while the quarter before that showed ‪259.14 M‬ CNY of net income which accounts for −22.62% change. Track more DASHENLIN PHARMACEUTICAL GROUP financial stats to get the full picture.
DASHENLIN PHARMACEUTICAL GROUP dividend yield was 1.24% in 2023, and payout ratio reached 30.10%. The year before the numbers were 1.52% and 54.85% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 30, 2024, the company has ‪45.47 K‬ employees. See our rating of the largest employees — is DASHENLIN PHARMACEUTICAL GROUP on this list?
Like other stocks, 603233 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DASHENLIN PHARMACEUTICAL GROUP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DASHENLIN PHARMACEUTICAL GROUP technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DASHENLIN PHARMACEUTICAL GROUP stock shows the sell signal. See more of DASHENLIN PHARMACEUTICAL GROUP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.